8-K
AYTU BIOPHARMA, INC (AYTU)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2022
AYTU BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
| | | |||
|---|---|---|---|---|
| Delaware | **** | 001-38247 | **** | 47-0883144 |
| (State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
373 Inverness Parkway , Suite 206
Englewood , CO **** 80112
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: ( 720 ) 437-6580
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | |||
|---|---|---|---|---|
| Title of each class | **** | Trading Symbol(s) | **** | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share | | AYTU | | The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On November 16, 2022, Aytu BioPharma, Inc. (the “Company”) announced the passing of Michael Macaluso, Co-Founder and founding board member of Aytu BioPharma. A copy of the Company’s press release passing is attached as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| | | |
|---|---|---|
| Exhibit | **** | Item |
| 99.1 | | Press release dated November 16, 2022 |
| 104 | | Cover Page Interactive Data File (formatted as inline XBRL). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | AYTU BIOPHARMA, INC. | |
|---|---|---|
| | | |
| | | |
| Date: November 16, 2022 | By: | /s/ Mark Oki |
| | | Mark Oki |
| | | Chief Financial Officer |
Exhibit 99.1
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
ENGLEWOOD, CO / November 16, 2022 / Aytu BioPharma, Inc. (the Company or “Aytu”) (Nasdaq: AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced the passing of Michael Macaluso, Co-Founder and founding board member of Aytu.
“On behalf of Aytu BioPharma, our employees, our Board of Directors, and the Denver-area life sciences community, we extend our deepest condolences to Mike's family and friends," said Josh Disbrow, Chief Executive Officer of Aytu BioPharma. "Mike was a strong, supportive voice for Aytu since we founded the Company in 2015. It has been a privilege to know and work alongside with Mike, and we are grateful for his many contributions, insight, and counsel. Mike will be sorely missed by us all."
Mr. Macaluso had been a director of Aytu since the Company’s formation in April 2015 and served as the Chair of the Aytu Board's Compensation Committee and was a member of the Audit and Nominating & Corporate Governance Committees. Mr. Macaluso’s successful entrepreneurial career spanned four decades across various industries, including founding and leading multiple public life sciences enterprises. Along with co-founding Aytu, Mr. Macaluso was most recently the Chief Executive Officer, founder and Director of Ampio Pharmaceuticals and Ampio’s predecessor company DMI Life Sciences. Prior to entering the life sciences industry he was the founder and principal of International Printing and Publishing, managing all phases of its domestic and international commercial printing operations from 1989 until 1997, the owner of Page International Communications, a manufacturing business, from 1998 until 2001, and in 2001 formed Isolagen, serving as a Director and as President and Chief Executive Officer. Mr. Macaluso was a graduate of Canisius College and was inducted into the Canisus College Hall of Fame in 1989.
About Aytu BioPharma, Inc.
Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu's consumer health segment markets a range of over-the-counter medicines, personal care products, and dietary supplements addressing a range of common conditions including diabetes, allergy, hair regrowth, and gastrointestinal conditions. To learn more, please visit aytubio.com.
Contacts for Investors:
Mark Oki, Chief Financial Officer Aytu BioPharma, Inc. moki@aytubio.com
Robert Blum or Roger Weiss Lytham Partners AYTU@lythampartners.com
Source: Aytu BioPharma, Inc.